CBD Oil For Pressure Sores

A new study shows that a combination of CBD, terpenes, and flavonoids leads to rapid wound closure of previously non-healing venous leg ulcers. /PRNewswire/ — Using technology adapted from NASA’s Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating… Your access to this site has been limited by the site owner If you think you have been blocked in error, contact the owner of this site for assistance. If you are a WordPress user with

CBD for Venous Leg Ulcers: Complete Wound Closure in 81% Chronic Cases

In journalism and media industry for more than twenty years, worked for a number of media companies. Business editing, research and PR specialist. Covering industry and science news for Ilesol Pharmaceuticals.

CBD for Venous Leg Ulcers: Complete Wound Closure in 81% Chronic Cases

A new study shows that a combination of CBD, terpenes, and flavonoids improves the results of compression therapy in venous leg ulcers. With the application of the topical solution containing molecules naturally present in cannabis, the wounds rapidly healed in patients with chronic conditions. The scientists believe in the efficiency of CBD for venous leg ulcers as a promising novel supportive therapy.

Venous leg ulcers are a chronic problem in many countries, especially in Northern Europe and the US. The overall prevalence of this condition is 1% rising to 3% in patients over 65 years of age. The venous leg ulcers are formed in the skin over the ankles and often are painful. Their treatment includes standardized care, which relies on a reliable diagnosis, compression, and local wound care. The healing of these wounds is variable, with common recurrence.

A recent analysis of 1323 patients reported that the proportion of patients who achieved complete closure using compression therapy at three and six months was 42.2% and 48.6%, respectively.

A new study published in May 2021 in Experimental Dermatology shows that a combination of cannabidiol, terpenes, and flavonoids leads to rapid wound closure of previously non-healing venous leg ulcers among elderly and highly complex patients.

This prospective open-label cohort trial recruited 14 patients with 16 chronic and non-healing leg ulcers referred to a regional consultative wound management clinic in Toronto, Canada.

The median age of the patients was 75.8 years, all with chronic wounds. One 81-year old patient with a surgically fused ankle was affected by his wound for 12.2 years. More than half of the patients had moderate to severe lipodermatosclerosis, edema, and peripheral arterial disease, all of which are significant factors against wound closure.

All patients had venous leg ulcers for longer than six months that failed to close despite at least four weeks of compression therapy. All patients underwent duplex venous dopplers that confirmed the presence of venous incompetency, and wound biopsies were carried out to rule out neoplasm, vasculitis, and rare vasculopathy. All patients provided informed consent for treatment using cannabis-based medicines – VS-12 and VS-14.

The cannabis-based medicines in this trial were composed of mixtures of cannabinoids, terpenes, and flavonoids applied topically to the wound beds and peri-wound tissues. VS-12 and VS-14 were chemically equivalent but compounded in separate vehicles. Formula VS-12, applied to wound bed consisted of CBD 3.8 mg/ml, THC

CBD for venous leg ulcers: The treatment

Great results obtained in this study on CBD for venous leg ulcers resulted with the following methodology:

Treatments were carried out every second day and continued until complete wound closure,
defined as the wound bed being 100% epithelialized. On their initial visits, all patients’ degrees of global medical complexity was calculated using both the M3 multimorbidity index tool and the Palliative Performance Scale score (PPS). Qualitative clinical assessments of their degrees of lipodermatosclerosis, edema, and peripheral arterial disease were also scored and documented. Following gentle cleansing with sterile normal saline, each patient underwent application of evenly applied thin layers of VS-12 to the wound beds, and VS-14 to a 4-6 cm radial cuff of peri-wound integument every second day. Tissues were then covered with one layer each of Jelonet and Mesorb. This was followed by the application of inelastic compression bandages, chosen based upon patient preferences, using a spiral technique, between the level of the metatarsal phalangeal joints and the infra-popliteal space.

See also  CBD Oil Shop Leicester

Two-dimensional wound measurements, namely, widest width and longest length, were documented at each visit after debridement was carried out. Given the irregular and eclectic wound bed contours, the wound area calculations were approximated by matching them to various geometric shapes and applying their respective mathematical formulae. Data was also fitted to a linear regression model to report the general trend and the estimated time to complete wound closure. The observed time to complete wound closure, defined as the number of days since treatment onset to observe complete wound closure since the start of treatment, was calculated. The wound area data points were also fitted using a least-squares linear regression model. The slope was extracted to report both the absolute (cm² per 30 days) and relative (% of original wound area per 30 days) rates of wound healing. The estimated time to achieve wound healing, defined as the number of days since treatment onset for the linear fit line to reach zero was reported.

Rapid wound closure in 34 days

Complete wound closure, defined as being fully epithelialized, was achieved among 11 patients (79%) and 13 wounds (81%) within a median of 34 days. The three remaining patients were unavailable for follow-up because one of them moved out of the country, and two died of unrelated reasons. However, those three wounds also demonstrated progressive healing when last seen. There were no significant adverse reactions in any patients.

These positive outcomes are the result of potentiation and synergy between cannabinoids, terpenes, and flavonoids, the scientists conclude.

The rapid wound closure of previously non-healing venous leg ulcers among elderly and highly complex patients suggests that topical cannabis-based medicines may become effective adjuvants in conjunction with compression therapy. It may also indicate that they may have an even broader role within the skin and wound management.

Reviewed by Sasha Bajilo, founder of ILESOL Pharmaceuticals, an industrial scale producer of CBD products and formulations. Expert on Hemp/Cannabis policy, member of the Croatian Ministry of Health regulatory commission for medical cannabis.

Hospitals Succeed in Eliminating Deadly Bedsores

MANCHESTER, England and LOS ANGELES , Dec. 23, 2016 /PRNewswire/ — Using technology adapted from NASA’s Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating hospitals were able to eliminate the occurrence of new bedsores completely; an additional 3 hospitals achieved reductions ranging from 11% to 90%.

Nurses dramatically cut bedsore occurrence by detecting damage developing under patients’ skin early enough to intervene and reverse the damage. This marks a breakthrough in prevention of the chronic condition costing the UK £2.1bn annually, which claimed the life of Superman actor Christopher Reeve .

Bruin Biometrics (“BBI LLC”), which manufactures the early detection technology known as the SEM Scanner, enlisted 13 hospitals (including 10 NHS England Trusts) to participate in a novel Pressure Ulcer Prevention Program (PURP) incorporating SEM Scanner into existing care pathways for pressure ulcer prevention.

See also  Tickle Kitty CBD Oil

The findings from over 1200 patients scanned are the most comprehensive real-world evidence that this early detection technology enables nurses to prevent bedsores before they break through the skin, a conclusion that upends the prevailing view that bedsores cannot be diagnosed and treated until they have caused visible and irreversible damage to the skin’s surface.

“These data challenge existing practice that looks for visual changes to skin to initiate bedsore intervention,” BBI CEO Martin Burns said. “Scientific findings show that by the time damage is visible, it is far too late. Early detection changed the prognosis for millions of cancer survivors. A proactive approach to ‘Act Before Red’ is consistently doing the same for bedsores, on a large scale, across independent sites.”

“We reduced pressure ulcers in the ward concerned to zero during our Scanner trial – an achievement that, if we rolled out across our hospital, we estimate could save our hospital nearly £600,000 and release 1,420 hours of nurse productivity annually,” said Glenn Smith , a tissue viability and nutrition senior clinical nurse specialist/patient safety lead at St. Mary’s Hospital, part of the NHS Trust on the Isle of Wight, which has a large elderly population at risk for bedsores due to immobility.

“In our pilot program, which included over 200 patients, we reduced bedsore incidence by 90%,” said Rose Raizman , nurse practitioner, enterostomal therapist and pressure ulcer prevention at Scarborough and Rouge Hospital in Ontario, Canada . “SEM Scanner allows the clinician to ‘visualise pathology’ below the skin level before it becomes apparent at the surface, and should be used as the standard of care for pressure ulcer prevention.”

“The vast majority of nurses participating in our Scanner program said the device provided valuable clinical information,” added Parker Moss , chief technology and transformation officer at Virgin Care, which experienced a 95 percent drop in the bedsore rate during an evaluation of the device at Farnham Community Hospital in Surrey , where it provides services to the NHS.

SEM Scanner is a wireless non-invasive handheld device that assesses sub-epidermal moisture, or SEM, an indicator of early-stage damage beneath the skin surface as much as 10 days earlier than visual inspection by nurses.

SEM Scanner was conceived by Barbara Bates-Jensen , a wound care expert and professor at the University of California at Los Angeles ( UCLA ), and adapted from seismology technology used on NASA’s Mars landing craft to interrogate beneath the planet’s surface. Professor Bates-Jensen, Dr. Majid Sarrafzadeh , and Dr. William J. Kaiser , co-director of the UCLA Wireless Health Institute and a former engineer at Jet Propulsion Laboratories, partnered with BBI to adapt the space technology into the SEM Scanner.

Bedsores, also known as pressure ulcers, are chronic wounds to the skin and tissue that often develop in patients who are immobile.

Bedsores commonly lead to infection and death. In fact, bedsores kill more people annually than any form of cancer except lung cancer. There are nearly 500,000 bedsore cases annually in the UK.

Until now, diagnosis has relied on visual inspection by nurses, which is subjective and which can only identify bedsores once visible damage to the skin has already begun. With early-detection, experts believe that over 80% of early-stage pressure ulcers can be prevented.

See also  CBD Oil For Pain Topical Or Oral

“We’ve borrowed NASA’s concept of ‘Seeing the Unseen’ to develop the first clinically-proven method for detecting unseen bedsores and alerting healthcare practitioners in real time when they begin to form under the skin,” said Rachael Lester , BBI VP of Product. “With early detection, clinicians can initiate treatment before chronic damage develops. More and more clinicians are using the SEM Scanner and finding that they can overcome avoidable PUs, proving that ZERO is no longer Mission: Impossible.”

Real-world evaluation data presented by St. Mary’s Hospital (Improved Patient Safety with Use of the SEM Scanner) and Virgin Care (Chasing Zero. Results from a New Pressure Ulcer Prevention Bundle) at the Wounds UK annual conference November 14-16 in Harrogate and are now being released publicly for the first time.

About Bedsores
Bedsores, also known as pressure ulcers, are a common medical problem that can lead to pain, disfigurement, infection and death. Pressure ulcers are an area of localized damage to the skin and underlying tissue – usually around an area of bony prominence, such as the sacrum, coccyx, heels, and hips – that results from pressure involving shear and/or friction. Across Europe and the United States , it is estimated that 18%-25% of patients in both acute care and long-term care settings suffer from pressure ulcers, disproportionately impacting the elderly and patients with limited mobility. There are some 2.5 million pressure ulcer cases annually in the European Union, and nearly 500,000 in the United Kingdom , which spends £2.1bn, or 4% of the NHS budget, on the condition. In the U.S., some 2.5 million Americans develop pressure ulcers annually in acute care facilities, and 60,000 Americans die annually from pressure ulcer complications such as cancer, sepsis, cellulitis, and MRSA.

About BBI
Bruin Biometrics LLC, a pioneer in biometric-sensor based medical devices, is committed to the development of point-of-care diagnostic solutions for early detection and monitoring of chronic, preventable conditions. The company’s first product is the SEM Scanner, a hand-held non-invasive device that assesses sub-epidermal moisture, a biomarker which has been found to detect early-stage pressure ulcers as much as 10 days earlier than visual observation. Pressure ulcers affect approximately 25% of acute care hospital and long-term care patients – typically the elderly and immobile. SEM Scanner is CE Mark approved and is currently in full commercial launch in the EU and Canada . SEM Scanner is not currently for sale in the United States .

BBI is also developing OrthoSonos, a non-invasive device for real-time orthopaedic joint monitoring and assessment of prosthetic implant failure; and P02M, the first device for monitoring tissue oxygenation at a specific location in real time. P02M is initially being tested for continual monitoring of tissue and vascular viability in the feet of diabetics. Diabetes can cause peripheral artery disease and peripheral neuropathy, putting patients at risk for foot ulcers.

BBI is based in Los Angeles and maintains a European office in Manchester, UK .

Your access to this site has been limited by the site owner

If you think you have been blocked in error, contact the owner of this site for assistance.

If you are a WordPress user with administrative privileges on this site please enter your email in the box below and click “Send”. You will then receive an email that helps you regain access.

Block Technical Data

Block Reason: Access from your area has been temporarily limited for security reasons
Time: Mon, 22 Aug 2022 7:39:21 GMT